- AU$7.26m
- AU$7.11m
- AU$0.41m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.66 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -166.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.02 | 0.18 | 0.05 | 1.21 | 0.41 | n/a | n/a | 21.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
InhaleRx Limited is an Australia-based clinical stage drug development company. The Company is focused on developing onset, inhaled therapies to address unmet medical needs in pain management and mental health sectors. The Company is focused on the development of IRX211 to treat Breakthrough Cancer Pain (BTcP), and IRX-616a to treat panic disorders. The Company’s operates through single segment that is the development of medical technologies. Its IRX-211 focuses on the management of BTcP with non-opioid, onset inhaled therapy. The Phase I clinical trials for IRX-211 have been completed. Its IRX-616a is an approved inhaled medication for panic disorder, offering a novel treatment avenue. It holds a patent that has been approved, and provisional patents have been lodged. The Company has identified some composition properties in the way the IRX211 drug device has performed and focused on developing resulting novel intellectual property in consultation with its patent attorneys.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- April 13th, 2016
- Public Since
- January 11th, 2017
- No. of Shareholders
- 568
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 213,448,224
- Address
- Level 5, 126 Phillip Street, SYDNEY, 2000
- Web
- https://inhalerx.com.au/
- Phone
- +61 383955446
- Auditors
- RSM Australia Partners
Upcoming Events for IRX
Similar to IRX
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 21:17 UTC, shares in Inhalerx are trading at AU$0.03. This share price information is delayed by 15 minutes.
Shares in Inhalerx last closed at AU$0.03 and the price had moved by +30.77% over the past 365 days. In terms of relative price strength the Inhalerx share price has outperformed the ASX All Ordinaries Index by +19.96% over the past year.
There is no consensus recommendation for this security.
Find out moreInhalerx does not currently pay a dividend.
Inhalerx does not currently pay a dividend.
Inhalerx does not currently pay a dividend.
To buy shares in Inhalerx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.03, shares in Inhalerx had a market capitalisation of AU$7.26m.
Here are the trading details for Inhalerx:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IRX
Based on an overall assessment of its quality, value and momentum Inhalerx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inhalerx. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +62.29%.
As of the last closing price of AU$0.03, shares in Inhalerx were trading +2.79% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Inhalerx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Inhalerx's management team is headed by:
- Sean Williams - NEC
- Darryl Davies - EDR
- Elizabeth Spooner - SEC
- Nova Taylor - SEC
- Andrew Saich - NED